BMC Musculoskeletal Disorders 2002 3: 21 Jonathan Raphael , Jane Southall , Gareth Treharne and George Kitas
Background: To investigate the effects of intravenous lignocaine infusions (IV lignocaine) in fibromyalgia
Methods: Prospective study of the adverse effects of IV lignocaine in 106 patients with fibromyalgia; retrospective questionnaire study of the efficacy of IV lignocaine in 50 patients with fibromyalgia
Results: Prospective study: Two major( pulmonary oedema and supraventricular tachycardia) and 42 minor side-effects were reported. None had long-term sequelae. The commonest was hypotension (17 cases). Retrospective study: Pain and a range of psychsocial measures ( on single 11-point scales) improved significantly after treatment. There was no effect of the treatment on work status. The average duration of pain relief after the 6-day course of treatment was 11.5+/-6.5 weeks.
Conclusions: Intravenous lignocaine appears to be both safe and of benefit in improving pain and quality of life for patients with fibromyalgia . This needs to be confirmed in prospective randomised controlled trials.